PL1689391T3 - Pochodne 5-fenylo-4-metylo-tiazol-2-ilo-aminy jako inhibitory enzymów - kinaz fosfatydyloinozytolu 3 (PI3) do leczenia zapalnych chorób dróg oddechowych - Google Patents

Pochodne 5-fenylo-4-metylo-tiazol-2-ilo-aminy jako inhibitory enzymów - kinaz fosfatydyloinozytolu 3 (PI3) do leczenia zapalnych chorób dróg oddechowych

Info

Publication number: PL1689391T3
Authority: PL; Poland
Prior art keywords: phosphatidylinositol; thiazol; inhibitors; phenyl; methyl
Prior art date: 2003-08-28

Application number

PL04764560T

Other languages

English (en)

Inventor

G C Bloomfield

Ian Bruce

Judy Fox Hayler

C Leblanc

Grand D M Le

Clive Mccarthy

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-28

Filing date

2004-08-27

Publication date

2009-09-30

2004-08-27 Application filed by Novartis Ag filed Critical Novartis Ag

2009-09-30 Publication of PL1689391T3 publication Critical patent/PL1689391T3/pl

Links

XSTQXTKOICQHDC-UHFFFAOYSA-N 4-methyl-5-phenyl-1,3-thiazol-2-amine Chemical class N1=C(N)SC(C=2C=CC=CC=2)=C1C XSTQXTKOICQHDC-UHFFFAOYSA-N 0.000 title 1
108091007960 PI3Ks Proteins 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
208000023504 respiratory system disease Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Thiazole And Isothizaole Compounds (AREA)

PL04764560T 2003-08-28 2004-08-27 Pochodne 5-fenylo-4-metylo-tiazol-2-ilo-aminy jako inhibitory enzymów - kinaz fosfatydyloinozytolu 3 (PI3) do leczenia zapalnych chorób dróg oddechowych PL1689391T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0320197.7A GB0320197D0 (en)	2003-08-28	2003-08-28	Organic compounds
EP04764560A EP1689391B1 (en)	2003-08-28	2004-08-27	5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
PCT/EP2004/009586 WO2005021519A2 (en)	2003-08-28	2004-08-27	5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases

Publications (1)

Publication Number	Publication Date
PL1689391T3 true PL1689391T3 (pl)	2009-09-30

Family

ID=28686509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04764560T PL1689391T3 (pl)	2003-08-28	2004-08-27	Pochodne 5-fenylo-4-metylo-tiazol-2-ilo-aminy jako inhibitory enzymów - kinaz fosfatydyloinozytolu 3 (PI3) do leczenia zapalnych chorób dróg oddechowych

Country Status (33)

Country	Link
US (3)	US7902375B2 (pl)
EP (1)	EP1689391B1 (pl)
JP (1)	JP4574618B2 (pl)
KR (1)	KR100774038B1 (pl)
CN (1)	CN1838953B (pl)
AR (1)	AR045510A1 (pl)
AT (1)	ATE429225T1 (pl)
AU (1)	AU2004268050B2 (pl)
BR (1)	BRPI0413934A (pl)
CA (1)	CA2533175A1 (pl)
CY (1)	CY1109227T1 (pl)
DE (1)	DE602004020793D1 (pl)
DK (1)	DK1689391T3 (pl)
EC (1)	ECSP066383A (pl)
ES (1)	ES2323000T3 (pl)
GB (1)	GB0320197D0 (pl)
HR (1)	HRP20090340T1 (pl)
IL (1)	IL173035A0 (pl)
IS (1)	IS2690B (pl)
MA (1)	MA28007A1 (pl)
MX (1)	MXPA06002217A (pl)
MY (1)	MY135050A (pl)
NO (1)	NO20061406L (pl)
NZ (1)	NZ545139A (pl)
PE (1)	PE20050872A1 (pl)
PL (1)	PL1689391T3 (pl)
PT (1)	PT1689391E (pl)
RU (1)	RU2382783C2 (pl)
SI (1)	SI1689391T1 (pl)
TN (1)	TNSN06064A1 (pl)
TW (1)	TWI347941B (pl)
WO (1)	WO2005021519A2 (pl)
ZA (1)	ZA200600415B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2005118543A1 (ja) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	キナーゼ阻害薬およびその用途
WO2006037468A1 (en) *	2004-09-30	2006-04-13	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Hiv reverse transcriptase inhibitors
BRPI0611029A2 (pt) *	2005-05-24	2010-08-10	Serono Lab	derivados de tiazol e uso dos mesmos
EP1888546B1 (en)	2005-05-24	2015-07-08	Merck Serono SA	Thiazole derivatives and use thereof
ZA200801822B (en)	2005-08-26	2009-09-30	Serono Lab	Pyrazine derivatives and use as p13k inhibitors
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
EP1991528A2 (en) *	2006-01-18	2008-11-19	Siena Biotech S.p.A.	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
GB0608854D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	P13 kinase inhibitors
GB0608823D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
GB0610243D0 (en) *	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
ZA200904857B (en)	2007-02-22	2010-09-29	Merck Serono Sa	Quinoxaline compounds and use thereof
WO2009023059A2 (en)	2007-06-01	2009-02-19	The Trustees Of Princeton University	Treatment of viral infections by modulation of host cell metabolic pathways
WO2009080705A2 (en) *	2007-12-20	2009-07-02	Novartis Ag	Bis-thiazole derivatives, process for their preparation and their use as medicaments
JP2011506560A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) *	2008-09-22	2013-06-12	北京摩力克科技有限公司	噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
WO2010091996A1 (en)	2009-02-12	2010-08-19	Merck Serono S.A.	2-morpholino-pyrido[3,2-d]pyrimidines
RS53830B1 (sr) *	2009-04-30	2015-06-30	Glaxo Group Limited	Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
EP2440556A1 (en) *	2009-06-10	2012-04-18	Vertex Pharmaceuticals Incorporated	Inhibitors of phosphatidylinositol 3-kinase
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
EA201200087A1 (ru)	2009-07-02	2012-07-30	Новартис Аг	2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
EP2492269A4 (en)	2009-10-19	2013-08-07	Taisho Pharmaceutical Co Ltd	aminothiazole
MX2012005518A (es)	2009-11-13	2012-06-19	Merck Serono Sa	Derivados de pirazol amina triciclica.
BR112012019459A2 (pt)	2010-02-03	2017-10-17	Signal Pharm Llc	identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
EP2727920B1 (en) *	2011-07-29	2016-11-02	FUJIFILM Corporation	1,5-naphthyridine derivative or salt thereof
CA2843887A1 (en)	2011-08-03	2013-02-07	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for lkb1 status
EP2763532B1 (en)	2011-10-05	2018-09-19	The Board of Trustees of the Leland Stanford Junior University	Pi-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3549940A1 (en)	2013-04-17	2019-10-09	Signal Pharmaceuticals, LLC	Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2908742C (en)	2013-04-17	2021-06-01	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172425A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
MY189663A (en)	2013-04-17	2022-02-23	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1221168A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
WO2014172436A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP6382946B2 (ja)	2013-04-17	2018-08-29	シグナルファーマシューティカルズ，エルエルシー	ジヒドロピラジノ−ピラジンによる癌治療
CN107474051B (zh)	2013-05-29	2020-10-30	西格诺药品有限公司	二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160880A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016149756A1 (en) *	2015-03-23	2016-09-29	The University Of Melbourne	Treatment of respiratory diseases
HK1252693A1 (zh) *	2015-06-30	2019-05-31	Dana Farber Cancer Institute, Inc.	Egfr抑制剂及其使用方法
ES3010661T3 (en)	2016-02-26	2025-04-04	Univ Leland Stanford Junior	Pi-kinase inhibitors with anti-infective activity
EA036176B1 (ru) *	2016-09-22	2020-10-09	Астразенека Аб	Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
IL271491B2 (en)	2017-06-22	2023-09-01	Celgene Corp	Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CA3134417A1 (en)	2019-03-21	2020-09-24	The Board Of Trustees Of The Leland Stanford Junior University	Pi4-kinase inhibitors and methods of using the same
AR121506A1 (es)	2020-03-03	2022-06-08	Pic Therapeutics Inc	Inhibidores del eif4e y sus usos
IL310924A (en)	2021-08-25	2024-04-01	Pic Therapeutics Inc	Eif4e inhibitors and uses thereof
US12157732B2 (en)	2021-08-25	2024-12-03	PIC Therapeutics, Inc.	eIF4E inhibitors and uses thereof
CN116874442B (zh) *	2023-07-27	2025-10-24	武汉呈瑞生物医药科技有限公司	一种有机化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1279531A1 (ru) *	1983-02-14	1986-12-23	Nippon Soda Co	"cпocoб пoлучehия пpoизboдhыx tиaзoлиhotpиaзиha"
EP0589985A1 (en) *	1991-06-21	1994-04-06	Boehringer Mannheim Italia S.P.A.	2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
MXPA02002559A (es)	1999-09-10	2002-07-30	Merck & Co Inc	Inhibidores de tirosina cinasa.
US6667300B2 (en) *	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
EP1294690A2 (en) *	2000-06-21	2003-03-26	Bristol-Myers Squibb Pharma Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2002010162A1 (en) *	2000-07-26	2002-02-07	Bristol-Myers Squibb Company	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
US7265134B2 (en) *	2001-08-17	2007-09-04	Merck & Co., Inc.	Tyrosine kinase inhibitors
AR038703A1 (es)	2002-02-28	2005-01-26	Novartis Ag	Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3

2003
- 2003-08-28 GB GBGB0320197.7A patent/GB0320197D0/en not_active Ceased
2004
- 2004-08-26 TW TW093125599A patent/TWI347941B/zh not_active IP Right Cessation
- 2004-08-26 PE PE2004000820A patent/PE20050872A1/es not_active Application Discontinuation
- 2004-08-26 AR ARP040103072A patent/AR045510A1/es not_active Application Discontinuation
- 2004-08-27 CN CN2004800237755A patent/CN1838953B/zh not_active Expired - Fee Related
- 2004-08-27 MX MXPA06002217A patent/MXPA06002217A/es active IP Right Grant
- 2004-08-27 PL PL04764560T patent/PL1689391T3/pl unknown
- 2004-08-27 AT AT04764560T patent/ATE429225T1/de active
- 2004-08-27 BR BRPI0413934-8A patent/BRPI0413934A/pt not_active IP Right Cessation
- 2004-08-27 RU RU2006109545/04A patent/RU2382783C2/ru not_active IP Right Cessation
- 2004-08-27 JP JP2006524337A patent/JP4574618B2/ja not_active Expired - Fee Related
- 2004-08-27 EP EP04764560A patent/EP1689391B1/en not_active Expired - Lifetime
- 2004-08-27 KR KR1020067004006A patent/KR100774038B1/ko not_active Expired - Fee Related
- 2004-08-27 US US10/568,053 patent/US7902375B2/en not_active Expired - Fee Related
- 2004-08-27 MY MYPI20043510A patent/MY135050A/en unknown
- 2004-08-27 DK DK04764560T patent/DK1689391T3/da active
- 2004-08-27 NZ NZ545139A patent/NZ545139A/en not_active IP Right Cessation
- 2004-08-27 PT PT04764560T patent/PT1689391E/pt unknown
- 2004-08-27 CA CA002533175A patent/CA2533175A1/en not_active Abandoned
- 2004-08-27 AU AU2004268050A patent/AU2004268050B2/en not_active Ceased
- 2004-08-27 HR HR20090340T patent/HRP20090340T1/xx unknown
- 2004-08-27 WO PCT/EP2004/009586 patent/WO2005021519A2/en not_active Ceased
- 2004-08-27 ES ES04764560T patent/ES2323000T3/es not_active Expired - Lifetime
- 2004-08-27 DE DE602004020793T patent/DE602004020793D1/de not_active Expired - Lifetime
- 2004-08-27 SI SI200431138T patent/SI1689391T1/sl unknown
2006
- 2006-01-09 IL IL173035A patent/IL173035A0/en unknown
- 2006-01-16 ZA ZA200600415A patent/ZA200600415B/en unknown
- 2006-02-17 EC EC2006006383A patent/ECSP066383A/es unknown
- 2006-02-27 MA MA28835A patent/MA28007A1/fr unknown
- 2006-02-27 TN TNP2006000064A patent/TNSN06064A1/en unknown
- 2006-03-24 IS IS8372A patent/IS2690B/is unknown
- 2006-03-28 NO NO20061406A patent/NO20061406L/no not_active Application Discontinuation
2009
- 2009-07-14 CY CY20091100743T patent/CY1109227T1/el unknown
2011
- 2011-02-03 US US13/020,211 patent/US20110124693A1/en not_active Abandoned
- 2011-02-03 US US13/020,247 patent/US20110124624A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1838953B (zh)	2011-02-02
MA28007A1 (fr)	2006-07-03
EP1689391A2 (en)	2006-08-16
JP4574618B2 (ja)	2010-11-04
MY135050A (en)	2008-01-31
TNSN06064A1 (en)	2007-10-03
EP1689391B1 (en)	2009-04-22
US20110124693A1 (en)	2011-05-26
JP2007504109A (ja)	2007-03-01
AU2004268050A1 (en)	2005-03-10
US20110124624A1 (en)	2011-05-26
DK1689391T3 (da)	2009-07-27
WO2005021519A3 (en)	2005-05-12
BRPI0413934A (pt)	2006-10-24
AR045510A1 (es)	2005-11-02
ECSP066383A (es)	2006-08-30
US20080280871A1 (en)	2008-11-13
NZ545139A (en)	2009-11-27
CN1838953A (zh)	2006-09-27
IS8372A (is)	2006-03-24
GB0320197D0 (en)	2003-10-01
KR20060060704A (ko)	2006-06-05
KR100774038B1 (ko)	2007-11-06
NO20061406L (no)	2006-08-25
IL173035A0 (en)	2006-06-11
PE20050872A1 (es)	2005-11-22
DE602004020793D1 (de)	2009-06-04
TW200517386A (en)	2005-06-01
SI1689391T1 (sl)	2009-08-31
TWI347941B (en)	2011-09-01
IS2690B (is)	2010-10-15
RU2006109545A (ru)	2007-10-10
HK1093688A1 (en)	2007-03-09
ZA200600415B (en)	2007-12-27
WO2005021519A2 (en)	2005-03-10
CY1109227T1 (el)	2014-07-02
PT1689391E (pt)	2009-06-19
CA2533175A1 (en)	2005-03-10
HRP20090340T1 (hr)	2009-07-31
ES2323000T3 (es)	2009-07-03
AU2004268050B2 (en)	2006-11-16
RU2382783C2 (ru)	2010-02-27
MXPA06002217A (es)	2006-04-27
ATE429225T1 (de)	2009-05-15
US7902375B2 (en)	2011-03-08

Publication	Publication Date	Title
PT1689391E (pt)	2009-06-19	Derivados 5-fenil-4-metil-tiazol-2-il-amina como inibidores de enzimas fosfatidilinositol 3 quinase (pi3) para o tratamento de doenças inflamatórias das vias respiratórias
GB0312832D0 (en)	2003-07-09	2-amino-pyridine derivatives useful for the treatment of diseases
PL362711A1 (pl)	2004-11-02	Pochodne morfolinoacetamidu do leczenia chorób zapalnych
AU2003206785A1 (en)	2003-09-02	Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
IL176233A0 (en)	2006-10-05	Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
AU2002310187A1 (en)	2002-12-09	Inhibitors of protein kinase for the treatment of disease
WO2004078712A3 (en)	2005-02-24	Isoquinoline derivatives and methods of use thereof
SI1725544T1 (sl)	2009-10-31	3-(4-heterociklil-1,2,3-triazol-1-il)-N-aril-benzamidi kot inhibitorji proizvodnje citokinov za zdravljenje kroničnih vnetnih bolezni
AU2003291992A1 (en)	2004-05-25	Phenylethanolamine derivatives for the treatment of respiratory diseases
IL189657A (en)	2010-12-30	Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
EP1592384A3 (en)	2005-10-13	Cop 1 for treatment of inflammatory bowel diseases
IL179906A0 (en)	2007-05-15	Novel hydantoin derivatives for the treatment of obstructive airway diseases
SI1487828T1 (sl)	2009-04-30	Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
AU2002233928A1 (en)	2002-07-01	Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2002303145A1 (en)	2002-10-08	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
IL172018A0 (en)	2009-02-11	Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
GB2410744B (en)	2006-04-12	Kinase inhibitors for the treatment of disease
ZA200605302B (en)	2007-04-25	Use of pentadienoic acid derivatives for the treatment of hyperuricemia
AU2003232844A1 (en)	2003-12-12	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
IL172377A0 (en)	2009-02-11	2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
ZA200603113B (en)	2007-08-29	Process for the preparation of risperidone
HK1071754A (en)	2005-07-29	Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2003216959A1 (en)	2003-09-02	Derivatives of thiazoles used for the treatment of neurological diseases
GB0312842D0 (en)	2003-07-09	2-amino-pyridine derivatives useful for the treatment of diseases
GB0312840D0 (en)	2003-07-09	2-amino-pyridine derivatives useful for the treatment of diseases